New! Sign up for our free email newsletter.
Science News
from research organizations

Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web

Date:
May 6, 1999
Source:
National Institute Of Allergy And Infectious Diseases
Summary:
An updated version of the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents has been posted to the AIDS Treatment Information Service Web site, www.hivatis.org. The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection.
Share:
FULL STORY

An updated version of the Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents has been posted to the AIDS Treatment Information Service (ATIS) Web site, http://www.hivatis.org.

The Guidelines were developed by the Panel on Clinical Practices for the Treatment of HIV Infection, a joint effort of the Department of Health and Human Services and the Henry J. Kaiser Family Foundation. The Guidelines were constructed as a "living document" and are updated frequently by the Panel.

"We feel that the Guidelines are an invaluable resource to all health care providers who care for HIV-infected individuals," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and co-chair of the Panel. The Guidelines were published in hard-copy form in the Morbidity and Mortality Weekly Report and in the Annals of Internal Medicine in 1998; however, they are updated frequently on the ATIS Web site. In addition, a hard copy of the most recent version of the Guidelines can be obtained for free by calling 1-800-448-0440.

Included in the latest version of the Guidelines are recommendations for the use of the recently approved anti-HIV drug abacavir (trade name Ziagen). Abacavir is a potent anti-HIV agent belonging to a class of drugs known as nucleoside analog reverse transcriptase inhibitors. This family of drugs also includes zidovudine (AZT) and lamivudine (3TC).

Clinical trials of abacavir combined with AZT and 3TC have shown that this combination suppresses HIV replication and boosts CD4+ T-cell counts to a degree comparable to widely used treatment regimens that combine a protease inhibitor drug with AZT and 3TC. CD4+ T cells are the crucial immune system cells depleted during the course of HIV disease.

The Panel notes that the potential advantages of the abacavir+AZT+3TC regimen include ease of administration (two pills twice daily), and the opportunity to save other classes of potent anti-HIV drugs, some with a higher incidence of undesirable side effects, for later use.

However, "The Panel is concerned about the ability of the abacavir+AZT+3TC regimen to adequately suppress HIV replication in individuals with high baseline levels of plasma viral load," says John G. Bartlett, M.D., chief of the division of infectious diseases at the Johns Hopkins University Medical Center and co-chair of the Panel.

In addition, abacavir has been associated with a hypersensitivity syndrome that can be life-threatening. In clinical trials, the hypersensitivity syndrome associated with abacavir occurred in approximately 5 percent of patients. In cases where the drug was discontinued because of hypersensitivity reactions and then re-introduced, life-threatening exacerbations of the hypersensitivity syndrome occurred. A medication guide and warning card providing information about recognizing the abacavir hypersensitivity syndrome should be dispensed with each abacavir prescription.

Currently, the Panel recommends using the abacavir-containing regimen as an "alternative" to the preferred regimens delineated in the Guidelines, which include two nucleoside analog reverse transcriptase inhibitors in combination with either a protease inhibitor or efavirenz, a non-nucleoside reverse transcriptase inhibitor.

The Panel also considered recently published data suggesting that HIV-infected women experience more rapid disease progression compared with men who have the same level of virus in their bloodstream. These data were obtained in studies of women who were injecting drug users, and the results have not been consistently observed in other studies. The Panel therefore did not recommend that women begin antiretroviral therapy earlier than men, but will continue to closely follow developments in this field.

The revised Guidelines also include a hypertext link to a brief discussion of the controversy surrounding the use of the drug hydroxyurea in the treatment of HIV infect

a>.

Story Source:

Materials provided by National Institute Of Allergy And Infectious Diseases. Note: Content may be edited for style and length.


Cite This Page:

National Institute Of Allergy And Infectious Diseases. "Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web." ScienceDaily. ScienceDaily, 6 May 1999. <www.sciencedaily.com/releases/1999/05/990505161644.htm>.
National Institute Of Allergy And Infectious Diseases. (1999, May 6). Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web. ScienceDaily. Retrieved November 2, 2024 from www.sciencedaily.com/releases/1999/05/990505161644.htm
National Institute Of Allergy And Infectious Diseases. "Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web." ScienceDaily. www.sciencedaily.com/releases/1999/05/990505161644.htm (accessed November 2, 2024).

Explore More

from ScienceDaily

RELATED STORIES